Company Profiles

CSE:AION

Aion Therapeutics

Niche Cannabis Extraction in British Columbia

AION:CNX
CSE:AION

Overview

Clinical laboratory research studies have clearly demonstrated that medical cannabis and medicinal mushrooms work together in symbiotic ways to promote healing. Aion Therapeutic (CSE: AION) elevates these findings by applying artificial intelligence (AI) techniques to create disease specific patentable medical cannabis/mushroom formulations, specifically designed for individual patients. This represents a historic breakthrough, bringing medical cannabis and medicinal mushrooms treatments into the realm of true personalized medicine.

Aion Therapeutic is a unique international pharmaceutical company specializing in blending the natural healing powers of medical cannabis and medicinal mushroom compounds to deliver a revolutionary new class of personalized therapeutics. In addition, with the recent opening of the new Aion International Center for Psychedelic Psychiatry, Aion leads the world in specialized use of psilocybin for the treatment of addiction and major depressive disorder (MDD).

In March 2021, the company filed 4 new patent applications with the United States Patent and Trademark Office that focus on the use of medicinal mushrooms in the treatment of the most prevalent of human cancers – including breast cancer – and the combination of medical cannabis and medicinal mushroom preparations for the treatment of serious bladder diseases. These new applications increase Aion’s intellectual property portfolio to a total of nine, with more expected in the very near future.

Psychedelic Psychiatry has the potential to change the lives of millions, reducing their disability and improving quality of life. The U.S. Food and Drug Administration (FDA) recently designated psilocybin
(a naturally occurring psychedelic compound produced by certain fungi) as a “breakthrough therapy” for the treatment of MDD, a depressive disorder. Along with MDD, the Aion International Center for Psychedelic Psychiatry will specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol and other drugs), depression and anxiety associated with life-threatening illnesses.

Being strategically positioned in Jamaica places Aion at the forefront of patentable therapeutic formulation discoveries, given the country is one of the very few places on earth where medical cannabis and medicinal mushrooms are either legal/regulated or not outlawed. Aion is free to perform combinatorial research and development, treat patients and move rapidly towards commercialization of its product lines.

Advanced R&D. Data mining. State-of-the-art machine learning. Infrastructure investment. Aion is well ahead of the curve in combining these elements to harness the symbiotic healing powers of medical cannabis and medicinal mushrooms to create formulations that allow individuals to combat some of the world’s most serious mental illnesses and diseases.

Aion Therapeutic is led by a strong management team including CEO Graham Simmonds, who brings over 20 years of public company management to the team. The executive team is complemented by experts Dr. Stephen Barhill and Chief Science Officer Dr. Herbert Fritsche, a world-renowned clinical chemist and former professor of laboratory medicine.

Aion Therapeutic’s Company Highlights

  • Aion Therapeutic applies artificial intelligence techniques to create disease specific patentable medical cannabis/mushroom formulations, specifically designed for individual patients.
  • The Aion International Center for Psychedelic Psychiatry was recently opened, leading the world in specialized use of psilocybin for the treatment of addiction and major depressive disorder.
  • The U.S. Food and Drug Administration recently designated psilocybin as a “breakthrough therapy” for the treatment of MDD, a depressive disorder.
  • 4 new patent applications filed with the United States Patent and Trademark Office that focus on the use of medicinal mushrooms in the treatment of the most prevalent of human cancers.
  • Aion Therapeutic is strategically positioned in Jamaica, one of the very few countries where medical cannabis and medicinal mushrooms are legal.
Get access to more exclusive Psychedelics Stock profiles here.

Recent News

Company News